Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SHRH1
The experimentally established mechanism targets of Cinnarizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinnarizine SCHEMBL16225873 | 1.00 | LMNA (1.00) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL44958 | 1.00 | LMNA (1.00) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL44957 | 1.00 | LMNA (1.00) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL3731525 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL3731524 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL10936874 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL10936878 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL11734590 | 0.93 | LMNA (0.86) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Clocinizine SCHEMBL30363 | 0.92 | LMNA (0.84) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL453260 | 0.92 | LMNA (0.84) | LMNAHIF1ACYP2D6CYP3A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038614-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-07-06 | — | — | EP | disclosed |
| EP-2892519-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015028659-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014037412-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2496226-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE | Pharnext (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012117073-A2 | NEW COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011054759-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE | PHARNEXT (FR) | 2011-05-12 | — | — | WO | disclosed |